8 completed. 4 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 4 |
| Phase 2 | 4 | Completed 4 |
Follow batefenterol: new trials by email Literature Review of batefenterol trials Research Report on batefenterol
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Batefenterol/Fluticasone Furoate in Treatment of Chronic Obstructive Pulmonary Disease Batefenterol + Fluticasone Furoate, Placebo, Albuterol - Pulmonary Disease, Chronic Obstructive | Phase 2 | Completed | GlaxoSmithKline | 63 | 2015-12-01 | 2020-07-21 |
| Dose-Finding Study of Batefenterol (GSK961081) Via Dry Powder Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD) Batefenterol, Umeclidinium/ Vilanterol, Placebo - Pulmonary Disease, Chronic Obstructive | Phase 2 | Completed | GlaxoSmithKline | 325 | 2015-11-06 | 2019-07-16 |
| Study to Determine the Pharmacokinetics of GSK961081 and Fluticasone Furoate When Administered Alone or in Combination GSK961081, Fluticasone furoate - Pulmonary Disease, Chronic Obstructive | Phase 1 | Completed | GlaxoSmithKline | 48 | 2014-02-19 | 2017-05-15 |
| A 4-week Dose-Ranging, Dose-Interval, Efficacy, Safety and Tolerability Study of GSK961081 in Subjects With Chronic Obstructive Pulmonary Disease (COPD) GSK961081, Salmeterol, Placebo - Pulmonary Disease, Chronic Obstructive | Phase 2 | Completed | GlaxoSmithKline | 437 | 2010-12-01 | 2016-12-01 |
| A Study to Investigate the Pharmacology of a Dual Pharmacophore in Healthy Volunteers GSK961081, GSK961081 matching placebo, Propranolol - Pulmonary Disease, Chronic Obstructive | Phase 1 | Completed | Theravance Biopharma | 23 | 2008-03-10 | 2021-10-06 |
| Succinate Salt Version of GSK961081 for Healthy Volunteers GSK961081, GSK961081 matching placebo - Pulmonary Disease, Chronic Obstructive | Phase 1 | Completed | Theravance Biopharma | 18 | 2007-11-29 | 2021-10-06 |
| A 2 Part Study Examining Doses Of GSK961081 In Healthy Volunteers And Then In COPD Patients GSK961081 - Pulmonary Disease, Chronic Obstructive | Phase 2 | Completed | GlaxoSmithKline | 82 | 2007-06-01 | 2017-02-02 |
| Study of GSK961081 in Healthy Volunteer Subjects GSK961081 15mcg SD, GSK961081 3mcg SD, GSK961081 50mcg SD - Pulmonary Disease, Chronic Obstructive | Phase 1 | Completed | Theravance Biopharma | 46 | 2005-11-07 | 2021-10-06 |
Pulmonary Disease, Chronic Obstructive (8)
GlaxoSmithKline (5) · Theravance Biopharma (3)
Germany (3) · South Africa (3) · United Kingdom (3) · United States (2) · Australia (1) · Estonia (1) · Netherlands (1) · Romania (1) · Russia (1) · Slovakia (1) · Sweden (1) · Ukraine (1)
2015 (1)